CGEN
Price
$1.65
Change
+$0.04 (+2.48%)
Updated
Mar 14 closing price
Capitalization
153.35M
54 days until earnings call
XOMAP
Price
$25.56
Change
-$0.15 (-0.58%)
Updated
Mar 14, 01:52 PM (EDT)
Capitalization
N/A
Ad is loading...

CGEN vs XOMAP

Header iconCGEN vs XOMAP Comparison
Open Charts CGEN vs XOMAPBanner chart's image
Compugen
Price$1.65
Change+$0.04 (+2.48%)
Volume$207.94K
Capitalization153.35M
XOMA
Price$25.56
Change-$0.15 (-0.58%)
VolumeN/A
CapitalizationN/A
CGEN vs XOMAP Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. XOMAP commentary
Mar 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and XOMAP is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 16, 2025
Stock price -- (CGEN: $1.65 vs. XOMAP: $25.60)
Brand notoriety: CGEN and XOMAP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 27% vs. XOMAP: 188%
Market capitalization -- CGEN: $153.35M vs. XOMAP: $0
CGEN [@Biotechnology] is valued at $153.35M. XOMAP’s [@Biotechnology] market capitalization is $0. The market cap for tickers in the [@Biotechnology] industry ranges from $340.08B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileXOMAP’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • XOMAP’s FA Score: 1 green, 4 red.
According to our system of comparison, both CGEN and XOMAP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish.

  • CGEN’s TA Score: 4 bullish, 4 bearish.

Price Growth

CGEN (@Biotechnology) experienced а -0.60% price change this week, while XOMAP (@Biotechnology) price change was -0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.40%. For the same industry, the average monthly price growth was -6.10%, and the average quarterly price growth was -7.72%.

Reported Earning Dates

CGEN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN YTD gains are higher at: 7.843 vs. XOMAP (1.022). CGEN has higher annual earnings (EBITDA): 10.6M vs. XOMAP (-18.71M). CGEN has more cash in the bank: 113M vs. XOMAP (93.3M). CGEN has less debt than XOMAP: CGEN (2.95M) vs XOMAP (119M). CGEN has higher revenues than XOMAP: CGEN (59.9M) vs XOMAP (9.71M).
CGENXOMAPCGEN / XOMAP
Capitalization153MN/A-
EBITDA10.6M-18.71M-57%
Gain YTD7.8431.022767%
P/E Ratio64.00N/A-
Revenue59.9M9.71M617%
Total Cash113M93.3M121%
Total Debt2.95M119M2%
FUNDAMENTALS RATINGS
CGEN: Fundamental Ratings
CGEN
OUTLOOK RATING
1..100
61
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
83
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGBRX16.47N/A
N/A
MFS Global Total Return R2
FVILX5.65N/A
N/A
Forester Value I
GSAOX14.75N/A
N/A
Goldman Sachs Small Cap Gr Insghts A
PMAIX11.81N/A
N/A
Pioneer Multi-Asset Income A
GMYPX16.16N/A
N/A
Goldman Sachs Large Cap Value P

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+2.48%
NURPF - CGEN
46%
Loosely correlated
N/A
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
N/A
CYTK - CGEN
38%
Loosely correlated
-0.09%
AXON - CGEN
36%
Loosely correlated
+4.06%
More

XOMAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMAP has been loosely correlated with AMLX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMAP jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMAP
1D Price
Change %
XOMAP100%
N/A
AMLX - XOMAP
51%
Loosely correlated
-1.09%
XOMAO - XOMAP
48%
Loosely correlated
-0.03%
CGEN - XOMAP
31%
Poorly correlated
+2.48%
MGTX - XOMAP
26%
Poorly correlated
-5.58%
NRXP - XOMAP
25%
Poorly correlated
+13.53%
More